Chen Xu, Zhang Xiaolong, Zhu Xuequan, Wang Gang
Beijing Key Laboratory of Mental Disorders, The National Clinical Research Center for Mental Disorders, Beijing Anding Hospital, Capital Medical University, Beijing, China.
Advanced Innovation Center for Human Brain Protection, Capital Medical University, Beijing, China.
Front Psychiatry. 2021 Jan 12;11:585920. doi: 10.3389/fpsyt.2020.585920. eCollection 2020.
Subclinical depression is a prevalent mental health problem and increases the incidence of the onset of major mood disorders, such as major depressive disorder (MDD). Psychological interventions have been proved to be effective for reducing depressive symptoms for people with subclinical depression and can prevent the onset of MDD. However, people have limited access to face-to-face psychotherapy. Internet-based psychological intervention is an alternative treatment option. The aim of the study is to evaluate the efficacy of MoodBox, an online psychological intervention program, for subclinical depression. This study is a multicenter, randomized, controlled, non-blinded superiority study with three parallel groups. A total of 435 first-year university students with subclinical depression will be recruited. Eligible participants will be randomly assigned to the MoodBox group, the online psychoeducation group, and the naturalistic observation group at a ratio of 1:1:1. The intervention period is 8 weeks, and participants will be continuously followed up for 1 year. The primary outcome of the study is the efficacy of the intervention, defined as measured by the Patient Health Questionnaire (PHQ-9). This is the first study to innovatively develop and test an intervention to improve psychological well-being and decrease the incidence of MDD in a subclinical depression population in China. Once proven effective and acceptable, MoodBox could be potentially integrated into the routine clinical service to facilitate the management for people with subclinical depression. The trial is registered with the Chinese Clinical Trial Registry on 21 July 2020 (No. ChiCTR2000034826).
亚临床抑郁是一种普遍存在的心理健康问题,会增加重度情绪障碍(如重度抑郁症,MDD)的发病几率。心理干预已被证明对减轻亚临床抑郁患者的抑郁症状有效,且能预防MDD的发作。然而,人们获得面对面心理治疗的机会有限。基于互联网的心理干预是一种替代治疗选择。本研究旨在评估在线心理干预项目MoodBox对亚临床抑郁的疗效。 本研究是一项多中心、随机、对照、非盲的优效性研究,设有三个平行组。将招募总共435名患有亚临床抑郁的大学一年级学生。符合条件的参与者将按1:1:1的比例随机分配到MoodBox组、在线心理教育组和自然观察组。干预期为8周,参与者将接受为期1年的持续随访。该研究的主要结果是干预的疗效,通过患者健康问卷(PHQ-9)进行衡量。 这是中国首个创新性开发并测试一种干预措施,以改善亚临床抑郁人群的心理健康并降低MDD发病率的研究。一旦被证明有效且可接受,MoodBox可能会被纳入常规临床服务,以促进对亚临床抑郁患者的管理。该试验于2020年7月21日在中国临床试验注册中心注册(注册号:ChiCTR2000034826)。